Grifols, S.A. (BME:GRF)

Revenue by Product

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Biopharma	6.14B
Biopharma Growth	10.51%
Diagnostic	644.90M
Diagnostic Growth	-3.79%
Bio Supplies	215.66M
Bio Supplies Growth	34.83%
Other	209.23M
Other Growth	2.84%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
United States and Canada	4.09B
United States and Canada Growth	4.82%
Rest of World	1.58B
Rest of World Growth	10.22%
Rest of European Union	1.12B
Rest of European Union Growth	25.22%
Spain	423.08M
Spain Growth	16.59%